Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists

Evaluation of Eravacycline: A Novel Fluorocycline

(2020) Sara Alosaimy et al.   PHARMACOTHERAPY

Prolonged infusion of beta-lactam antibiotics for Gram-negative infections

(2020) Mohd H. Abdul-Aziz et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial

(2020) Lorenz Leitner et al.   LANCET INFECTIOUS DISEASES

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

(2020) Matteo Bassetti et al.   LANCET INFECTIOUS DISEASES

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

(2020) Richard G Wunderink et al.   LANCET INFECTIOUS DISEASES

Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug‐Resistant Gram‐Negative Pathogens

(2020) Jacinda C. Abdul‐Mutakabbir et al.   PHARMACOTHERAPY

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

(2019) Brian T. Tsuji et al.   PHARMACOTHERAPY

Multidrug-resistant Acinetobacter baumannii infections: current evidence on treatment options and role of PK/PD in dose optimization

(2019) Sazlyna Mohd Sazlly Lim et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Biofilm prevention concentrations (BPC) of minocycline compared to polymyxin B, meropenem, and amikacin against Acinetobacter baumannii

(2019) Maya Beganovic et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit

(2019) Ying Xu et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Antimicrobial Resistance or Delayed Appropriate Therapy—Does One Influence Outcomes More Than the Other among Patients with Serious Infections due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae?

(2019) Thomas Lodise et al.   Open Forum Infectious Diseases

Efficacy of combinations of colistin with other antimicrobials involves membrane fluidity and efflux machinery

(2019) E. Armengol et al.   Infection and Drug Resistance

Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases

(2019) Jinhong Gong et al.   MEDICINE

Risk factors for the first episode of Acinetobacter baumannii resistant to colistin infection and outcome in critically ill patients

(2019) Konstantinos Mantzarlis et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat

(2019) David A. Butler et al.   Current Infectious Disease Reports

Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study

(2019) Matteo Bassetti et al.   Infection and Drug Resistance

636. Genome Epidemiology of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in the United States

(2019) Alina Iovleva et al.   Open Forum Infectious Diseases

In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii

(2019) Harald Seifert et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis

(2018) Konstantinos Z. Vardakas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii

(2018) Harald Seifert et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

(2018) Mical Paul et al.   LANCET INFECTIOUS DISEASES

Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials

(2018) Konstantinos Z Vardakas et al.   LANCET INFECTIOUS DISEASES

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

(2018) Evelina Tacconelli et al.   LANCET INFECTIOUS DISEASES

Differential characteristics of Acinetobacter baumannii colonization and infection: risk factors, clinical picture, and mortality

(2018) Andrés Martín-Aspas et al.   Infection and Drug Resistance

Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities

(2018) Muhammad Asif et al.   Infection and Drug Resistance

Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: characterization of carbapenemase genes and E-test evaluation of colistin-based combinations

(2018) Raghdaa A Ramadan et al.   Infection and Drug Resistance

IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections

(2018) Joseph S Solomkin et al.   CLINICAL INFECTIOUS DISEASES

Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by gram-negative bacilli: a systematic review

(2018) Aaron J Heffernan et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

(2018) Simon Portsmouth et al.   LANCET INFECTIOUS DISEASES

Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial

(2018) Patrick Jault et al.   LANCET INFECTIOUS DISEASES

Catheter removal and outcomes of multidrug-resistant central-line-associated bloodstream infection

(2018) Jason P. Burnham et al.   MEDICINE

Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit

(2018) Anne-Lise Munier et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Outer membrane protein A contributes to antimicrobial resistance of Acinetobacter baumannii through the OmpA-like domain

(2017) Hyo Il Kwon et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: A systematic review and meta-analysis

(2017) Haojun Chen et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Correlation between ability of biofilm formation with their responsible genes and MDR patterns in clinical and environmental Acinetobacter baumannii isolates

(2017) Ali Mohammadi Bardbari et al.   MICROBIAL PATHOGENESIS

In vitro Evaluation of the Colistin-Carbapenem Combination in Clinical Isolates of A. baumannii Using the Checkerboard, Etest, and Time-Kill Curve Techniques

(2017) Micheline A. H. Soudeiha et al.   Frontiers in Cellular and Infection Microbiology

Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial

(2017) Joseph Solomkin et al.   JAMA Surgery

In VitroActivity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii

(2016) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Use of Comparative Genomics To Characterize the Diversity of Acinetobacter baumannii Surveillance Isolates in a Health Care Institution

(2016) Lalena Wallace et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages

(2016) Agata Anna Cisek et al.   CURRENT MICROBIOLOGY

In VitroInteractions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-ResistantAcinetobacter baumannii

(2016) Gyun Cheol Park et al.   Annals of Laboratory Medicine

In Vitro Global Surveillance of Eravacycline and Comparators Against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Including Multidrug-Resistant (MDR) Isolates, Over a 3-Year Period (2013–2015)

(2016) Matteo Bassetti et al.   Open Forum Infectious Diseases

Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii

(2015) William F. Penwell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance

(2015) Zubair A. Qureshi et al.   CLINICAL INFECTIOUS DISEASES

Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence

(2015) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Tetracyclines for multidrug-resistant Acinetobacter baumannii infections

(2015) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

An Update on the arsenal for multidrug-resistant Acinetobacter infections: Polymyxin antibiotics

(2015) Zahra Kassamali et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women

(2014) Kevin P. Connors et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City

(2014) Marie Abdallah et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Stratification of the Impact of Inappropriate Empirical Antimicrobial Therapy for Gram-Negative Bloodstream Infections by Predicted Prognosis

(2014) Sarah E. Cain et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Update on Acinetobacter Species: Mechanisms of Antimicrobial Resistance and Contemporary In Vitro Activity of Minocycline and Other Treatment Options

(2014) Mariana Castanheira et al.   CLINICAL INFECTIOUS DISEASES

OXA  -Lactamases

(2014) B. A. Evans et al.   CLINICAL MICROBIOLOGY REVIEWS

Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

(2014) J. Alexander Viehman et al.   DRUGS

Role of OmpA in the Multidrug Resistance Phenotype of Acinetobacter baumannii

(2013) Younes Smani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Unique Structural Modifications Are Present in the Lipopolysaccharide from Colistin-Resistant Strains of Acinetobacter baumannii

(2013) Mark R. Pelletier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Contribution of Efflux Pumps, Porins, and β-Lactamases to Multidrug Resistance in Clinical Isolates of Acinetobacter baumannii

(2013) C. Rumbo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroResponses of Acinetobacter baumannii to Two- and Three-Drug Combinations following Exposure to Colistin and Doripenem

(2013) Louise M. Oleksiuk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria

(2013) Nicola Petrosillo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prolonging β-lactam infusion: A review of the rationale and evidence, and guidance for implementation

(2013) Shawn H. MacVane et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin–sulbactam and meropenem combination therapy

(2013) Yoichi Hiraki et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

TEM-1  -lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii

(2013) L. Krizova et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Risk factors for imipenem-nonsusceptible Acinetobacter nosocomialis bloodstream infection

(2013) Lei Huang et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens

(2013) Xavier Wittebole et al.   Virulence

Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010

(2012) Anne Marie Queenan et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Correlation Between Carbapenem Consumption and Antimicrobial Resistance Rates ofAcinetobacter baumanniiin a University-Affiliated Hospital in China

(2012) Jia Cao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Risk factors and outcomes in patients with carbapenem-resistant Acinetobacter infection

(2012) Astra Vitkauskiene et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter Baumannii

(2011) John S Esterly et al.   ANNALS OF PHARMACOTHERAPY

Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia

(2011) Christopher M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii

(2011) Marie Kempf et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Molecular Epidemiology of Carbapenem-Nonsusceptible Acinetobacter baumannii in the United States

(2011) Jennifer M. Adams-Haduch et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Potent Synergy and Sustained Bactericidal Activity of a Vancomycin-Colistin Combination versus Multidrug-Resistant Strains of Acinetobacter baumannii

(2010) N. C. Gordon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia

(2010) Aryun Kim et al.   CLINICAL THERAPEUTICS

Aminoglycoside Resistance and Susceptibility Testing Errors in Acinetobacter baumannii-calcoaceticus Complex

(2010) K. S. Akers et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Isolation and characterization of ϕAB2: a novel bacteriophage of Acinetobacter baumannii

(2010) Nien-Tsung Lin et al.   RESEARCH IN MICROBIOLOGY

Tetracycline Susceptibility Testing and Resistance Genes in Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Complex from a U.S. Military Hospital

(2009) K. S. Akers et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore

(2009) Tze-Peng Lim et al.   JOURNAL OF ANTIBIOTICS

Management of meningitis due to antibiotic-resistant Acinetobacter species

(2009) Baek-Nam Kim et al.   LANCET INFECTIOUS DISEASES

Genetic Basis of Multidrug Resistance in Acinetobacter baumannii Clinical Isolates at a Tertiary Medical Center in Pennsylvania

(2008) J. M. Adams-Haduch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients

(2008) Alexandre P. Zavascki et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia

(2008) Alex P. Betrosian et al.   JOURNAL OF INFECTION